$PFE Recent News Inversions are not such a sweet deal

New Post Public Reply Private Reply Replies (0) Message Board

Aug 25, 2014 at 11:46 AM

$PFE Recent News

Inversions are not such a sweet deal for fund investors 1:47 p.m. Aug. 18, 2014 - Chuck Jaffe
Tax inversions can be bad for shareholders — and for America 2:31 p.m. Aug. 17, 2014 - Chuck Jaffe
Investors sent on a wild ride by hostile deals 12:56 p.m. Aug. 15, 2014 - David Weidner
Timing this market is guaranteed to make you a loser 1:02 p.m. Aug. 8, 2014 - Mark Hulbert
Tax inversions help, not hurt, the economy 7:20 a.m. Aug. 8, 2014 - Diana Furchtgott-Roth
Mega caps with mega recommendations 7:54 a.m. Aug. 6, 2014 - Mark Hulbert
Zoetis narrows full-year earnings guidance 8:12 a.m. Aug. 5, 2014 - MarketWatch.com
‘Inversion’ payoff for shareholders is muted at tax time 11:42 a.m. Aug. 3, 2014 - Laura Saunders
5 ways to profit from sex (without having it) 8:45 a.m. Aug. 3, 2014 - Charles Passy
AstraZeneca raises earnings view as sales rise 3:01 a.m. July 31, 2014 - MarketWatch.com
Pfizer to buy Baxter’s vaccines for $635 million 8:32 a.m. July 30, 2014 - Anna Prior
U.S. stocks end choppy trade lower 4:16 p.m. July 29, 2014 - Carla Mozee
Herbalife sinks on disappointing results; Darden gains 3:16 p.m. July 29, 2014 - Angela Johnson
Newscast: Investors await Fed meeting 10:01 a.m. July 29, 2014 - MarketWatch
Newscast: Wall Street may gain ground 7:35 a.m. July 29, 2014 - MarketWatch
Pfizer shares rise 1.3% in premarket trade after Q2 results 7:25 a.m. July 29, 2014 - Tomi Kilgore
Pfizer profit rises above estimates 7:24 a.m. July 29, 2014 - MarketWatch.com
The market in a minute: What will GDP mean for the market? 12:47 p.m. July 28, 2014 - The Trading Deck
Correction: Blog points out Valeant's diverse portfolio is key to its success 1:53 p.m. July 21, 2014 - blogs.marketwatch.com
Two rules of thumb for dumping your financial adviser 2:36 p.m. July 18, 2014 - Mark Hulbert

Jackson Hole And Complacency 12:18 a.m. Aug. 24, 2014 - Seeking Alpha
Despite Gains, European Pharma Looks Sickly 1:41 a.m. Aug. 23, 2014 - Barrons.com
Durata exercises milestone payment deferral right 8:02 p.m. Aug. 22, 2014 - Seeking Alpha
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog 5:55 p.m. Aug. 22, 2014 - Zacks.com
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 3:46 p.m. Aug. 22, 2014 - CNW Group
FDA approves single-pill regimen HIV med 3:32 p.m. Aug. 22, 2014 - Seeking Alpha
Tonix Could Match Pfizer's Biggest Drug's Best Market 9:43 a.m. Aug. 22, 2014 - Seeking Alpha
Pfizer Inc. (PFE): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Aug. 22, 2014 - Zacks.com
Sweet Lawsuit Home, Alabama 7:35 p.m. Aug. 21, 2014 - The Wall Street Journal Interactive Edition
Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog 5:30 p.m. Aug. 21, 2014 - Zacks.com
FDA approves Eliquis label expansion 3:51 p.m. Aug. 21, 2014 - Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? 3:50 p.m. Aug. 21, 2014 - Seeking Alpha
ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms 2:14 p.m. Aug. 21, 2014 - 247WallSt.com
Contract Researcher Parexel Sees Growth In Biotech 2:00 p.m. Aug. 21, 2014 - Investors Business Daily
Pfizer may make another run at AstraZeneca by year end 11:47 a.m. Aug. 21, 2014 - Seeking Alpha
Illumina Forms Partnerships With Big Pharma Firms 11:03 a.m. Aug. 21, 2014 - Investors Business Daily
Grappling with Inversion-Induced Tax Hits 9:35 a.m. Aug. 21, 2014 - The Wall Street Journal Interactive Edition
Why AstraZeneca (AZN) Stock Is Higher Today 9:35 a.m. Aug. 21, 2014 - TheStreet.com
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog 4:27 p.m. Aug. 20, 2014 - Zacks.com
GlaxoSmithKline: The Bad Isn't All That Bad 3:39 p.m. Aug. 20, 2014 - Seeking Alpha

Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 9:00 a.m. Today - PR Newswire - PRF
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 3:46 p.m. Aug. 22, 2014 - PR Newswire - PRF
Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer 8:00 a.m. Aug. 21, 2014 - BusinessWire - BZX
Expanding IBD Research Through Collaboration 9:00 a.m. Aug. 20, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Premier Biotechnology & Anti-CTLA4 8:02 a.m. Aug. 18, 2014 - ACCESSWIRE
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA 8:00 a.m. Aug. 18, 2014 - BusinessWire - BZX
Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine 5:01 p.m. Aug. 14, 2014 - BusinessWire - BZX
Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older 5:43 p.m. Aug. 13, 2014 - BusinessWire - BZX
Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic PeripheralNeuropathy Lyrica® Studies Conducted in China 5:03 p.m. Aug. 12, 2014 - BusinessWire - BZX
Study Links Viagra(R) to Skin Cancer 11:20 a.m. Aug. 12, 2014 - Marketwire
Entia Biosciences' Supplements Could Prevent Dementia 9:55 a.m. Aug. 12, 2014 - ACCESSWIRE
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics 9:00 a.m. Aug. 12, 2014 - PR Newswire - PRF
23andMe Announces Agreement with Pfizer Inc. to Research Genetics of Ulcerative Colitis and Crohn's Disease 9:00 a.m. Aug. 12, 2014 - PR Newswire - PRF
Renal Pain Global Clinical Trials Review, H2, 2014 4:37 p.m. Aug. 11, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults 8:00 a.m. Aug. 7, 2014 - BusinessWire - BZX
Pain Therapeutics Reports Q2 2014 Financial Results 8:01 a.m. Aug. 5, 2014 - GlobeNewswire
Depomed Announces Appointment of R. Scott Shively as Chief Commercial Officer 4:01 p.m. Aug. 4, 2014 - PR Newswire - PRF
Rascal Flatts Joins the Thousands of People Who Choose Nexium® 24HR Every Day for Their Frequent Heartburn 8:01 a.m. Aug. 4, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

China's 15th Plan: Key Moves in the Capital Markets

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Superteam Wheels Rides Into Spain with RACEIT Deal

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Zinzino Eyes European Market With New Botanical Line

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...